Metformin promotes tau aggregation and exacerbates abnormal behavior in a mouse model of tauopathy

Abstract

BackgroundAlzheimer disease (AD) and other tauopathies develop cerebral intracellular inclusions of hyperphosphorylated tau. Epidemiological and experimental evidence suggests a clear link between type 2 diabetes mellitus and AD. In AD animal models, tau pathology is exacerbated by metabolic comorbidities, such as insulin resistance and diabetes. Within this context, anitidiabetic drugs, including the widely-prescribed insulin-sensitizing drug metformin, are currently being investigated for AD therapy. However, their efficacy for tauopathy in vivo has not been tested.ResultsHere, we report that in the P301S mutant human tau (P301S) transgenic mouse model of tauopathy, chronic administration of metformin exerts paradoxical effects on tau pathology. Despite reducing tau phosphorylation in the cortex and hippocampus via AMPK/mTOR and PP2A, metformin increases insoluble tau species (including tau oligomers) and the number of inclusions with β-sheet aggregates in the brain of P301S mice. In addition, metformin exacerbates hindlimb atrophy, increases P301S hyperactive behavior, induces tau cleavage by caspase 3 and disrupts synaptic structures.ConclusionsThese findings indicate that metformin pro-aggregation effects mitigate the potential benefits arising from its dephosphorylating action, possibly leading to an overall increase of the risk of tauopathy in elderly diabetic patients.Electronic supplementary materialThe online version of this article (doi:10.1186/s13024-016-0082-7) contains supplementary material, which is available to authorized users.

A Brief Overview of Tauopathy: Causes, Consequences, and Therapeutic Strategies

“…While studies in tau transgenic mice also report a reduction in disease-associated phosphotau in response to metformin treatment, the authors also report a metformin-induced increase in tau cleavage, aggregation, synaptic disruption, and hind limb atrophy. Based on these findings, the authors caution that treatment of diabetic patients with metformin may place them at higher risk for tauopathy [61]. …”

Metformin and ageing: improving ageing outcomes beyond glycaemic control

“…Researchers reported worsening tau aggregation and abnormal behaviour [57] or impaired spatial memory and visual acuity [58] in mouse models of ageing. Nevertheless, investigators from the DPPOS have just published an analysis of cognitive function, measured 8–10 years after therapy with metformin [59].…”

Parkinson';s Disease, Diabetes and Cognitive Impairment

“…A case-control study based in the United Kingdom suggested that metformin may be associated with an increased risk of AD in longterm use [84], and treatment of mice with metformin has been shown to increase tau protein aggregation [85]. However, the same study does also show metformin to reduce tau phosphorylation, leading to the authors concluding that the benefits are mitigated by negative effects, rather than metformin having an overall detrimental effect [85].…”